Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat
Public ClinicalTrials.gov record NCT03005717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study LIPO-202-CL-31 is a multi center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of LIPO-202 versus placebo on submental bulging due to subcutaneous fat. Approximately 150 participants of either gender who have a "Moderate Bulge" or "Large Bulge" in the submental fat (on Patient-Reported Submental Bulging Scale \[PR-SBS\] and Clinician-Reported Submental Bulging Scale \[CR-SBS\]) will be recruited for this study.
Study identification
- NCT ID
- NCT03005717
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 22, 2016 (Actual)
- Primary completion
- Jun 2, 2017 (Actual)
- Completion
- Jun 2, 2017 (Actual)
- Last update posted
- Oct 20, 2017
2016 – 2017
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Testing of Beverly Hills | Beverly Hills | California | 90210 | — |
| Ablon Skin Institute And Research Center | Manhattan Beach | California | 90266 | — |
| AboutSkin Research | Greenwood Village | Colorado | 80113 | — |
| Skin Research Institute | Coral Gables | Florida | 33146 | — |
| Grekin Skin Institute | Warren | Michigan | 48088 | — |
| Minnesota Clinical Study Center | Fridley | Minnesota | 55432 | — |
| Mercy Research | Washington | Missouri | 63090 | — |
| Skin Specialists, PC | Omaha | Nebraska | 68144 | — |
| Juva Skin & Laser Center | New York | New York | 10022 | — |
| Tennessee Clinical Research Center | Nashville | Tennessee | 37215 | — |
| Westlake Dermatology Clinical Research Center | Austin | Texas | 78746 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03005717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2017 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03005717 live on ClinicalTrials.gov.